Working Groups

The Clinical Research Unit (CRU) for healthcare-associated infections, headed by Dr. med. Siri Göpel, combines knowledge from clinical practice, microbiology, basic research and epidemiology. Scientists and physicians work closely together, investigate various aspects of hospital-associated ...

The Clinical Trials Platform at the Tübingen Institute of Tropical Medicine supports the development of new agents and vaccines against infectious diseases. It focuses on conducting experimental studies and first trials on humans. A special feature is the human malaria infection model, developed in ...

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating ...

Proteins form different conformations in combination with other proteins—as multimers or heterocomplexes—than when they are present as monomers. Static descriptions of protein structures are therefore often not sufficient to describe their dynamic properties. Nevertheless, current simulations of ...

Andreas Dräger's research group is dedicated to computational systems biology with a focus on infections and antibiotic-resistant pathogens. A primary goal is deriving model-driven new hypotheses with which increasing antibiotic resistance can be systematically combated. The group, which is based at ...

The majority of successful antibiotics are derived from microorganisms and the potential of finding new agents in this group is yet to be exploited. Using genome sequencing, scientists have frequently discovered gene clusters with potential antibiotic activity. However, synthesis does not occur ...

As part of a partnership, the so-called Eastern European Study Site (EESS) was set up in Bucharest (Romania) with the Marius-Nasta Institute and the affiliated tuberculosis hospital. Eastern European countries have a high occurrence of tuberculosis, and the number of multiresistant TB cases is ...

Professor Marc Stadler’s research group examines cultures of rare types of fungi and bacteria, predominantly from tropical regions, for their potential to develop new antibiotic substances. Thanks to international partnerships, these substances are isolated, identified and subsequently transferred ...

Ulrich Nübel’s group investigates the biosynthetic potential of myxobacteria and other groups of bacteria by means of genome analysis. State-of the art sequencing methods and comprehensive calculation capacities are available for this purpose at the Leibniz Institute DSMZ. The group has already ...

The HepNet Study-House connects individual trial centres in the hepatitis research field, creating a central platform for conducting clinical trials (investigator initiated trials). In addition, it establishes patient cohorts for viral hepatitis research. On the one hand, the Study-House is a point ...